

A T Pharma Solutions Limited

Annual Report and Unaudited Financial Statements
for the Year Ended 31 July 2018

A T Pharma Solutions Limited

Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u> to <u>3</u>
Notes to the Financial Statements	<u>4</u> to <u>6</u>

A T Pharma Solutions Limited

Company Information

Directors	Mrs A C Ralli-Thomas Mr D A Thomas
Registered office	The Orbit Business Centre Rhydycar Business Park Merthyr Tydfil Mid Glamorgan CF48 1DL
Accountants	Mitchell Meredith Limited Chartered Accountants The Hawthorns 6 North Road Cardiff CF10 3DU

A T Pharma Solutions Limited
(Registration number: 09696921)
Balance Sheet as at 31 July 2018

	Note	2018 £	2017 £
Fixed assets			
Tangible assets	<u>3</u>	518	691
Current assets			
Debtors	<u>4</u>	16,013	8,651
Cash at bank and in hand		4,347	6,243
		20,360	14,894
Creditors: Amounts falling due within one year	<u>5</u>	(18,554)	(11,662)
Net current assets		1,806	3,232
Total assets less current liabilities		2,324	3,923
Provisions for liabilities		(98)	(170)
Net assets		<u>2,226</u>	<u>3,753</u>
Capital and reserves			
Called up share capital		2	2
Profit and loss account		2,224	3,751
Total equity		<u>2,226</u>	<u>3,753</u>

The notes on pages 4 to 6 form an integral part of these financial statements.

A T Pharma Solutions Limited
(Registration number: 09696921)
Balance Sheet as at 31 July 2018

For the financial year ending 31 July 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 22 January 2019 and signed on its behalf by:

.....

Mrs A C Ralli-Thomas
Director

The notes on pages 4 to 6 form an integral part of these financial statements.
Page 3

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

1 General information

The company is a private company limited by share capital, incorporated in England and Wales.

The principal place of business is:

10 Hardwicke Court
Llandaff
Cardiff
CF5 2LB
United Kingdom

These financial statements were authorised for issue by the Board on 22 January 2019.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Furniture, fittings and equipment	20% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Stocks

Stocks are stated at the lower of cost and estimated selling price.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

3 Tangible assets

	Furniture, fittings and equipment £	Total £
Cost or valuation		
At 1 August 2017	864	864
At 31 July 2018	864	864
Depreciation		
At 1 August 2017	173	173
Charge for the year	173	173
At 31 July 2018	346	346
Carrying amount		
At 31 July 2018	518	518
At 31 July 2017	691	691

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

4 Debtors

	2018 £	2017 £
Trade debtors	3,407	2,045
Other debtors	12,606	6,606
Total current trade and other debtors	16,013	8,651

5 Creditors

Creditors: amounts falling due within one year

	Note	2018 £	2017 £
Due within one year			
Directors loan account		431	62
Taxation and social security		2,400	-
Other creditors		15,723	11,600
		18,554	11,662

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.